CN105688217A - Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix - Google Patents
Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix Download PDFInfo
- Publication number
- CN105688217A CN105688217A CN201610044368.7A CN201610044368A CN105688217A CN 105688217 A CN105688217 A CN 105688217A CN 201610044368 A CN201610044368 A CN 201610044368A CN 105688217 A CN105688217 A CN 105688217A
- Authority
- CN
- China
- Prior art keywords
- parts
- patch
- external use
- prepared
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000005075 mammary gland Anatomy 0.000 title abstract description 12
- 206010020718 hyperplasia Diseases 0.000 title abstract description 6
- 239000011159 matrix material Substances 0.000 title abstract 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 45
- 230000000149 penetrating effect Effects 0.000 claims abstract description 35
- 239000000843 powder Substances 0.000 claims abstract description 34
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000011975 tartaric acid Substances 0.000 claims abstract description 26
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 26
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 24
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract description 24
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract description 24
- 108010010803 Gelatin Proteins 0.000 claims abstract description 23
- 239000008273 gelatin Substances 0.000 claims abstract description 23
- 229920000159 gelatin Polymers 0.000 claims abstract description 23
- 235000019322 gelatine Nutrition 0.000 claims abstract description 23
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 23
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 21
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 20
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 20
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 20
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 20
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 19
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 19
- 239000008213 purified water Substances 0.000 claims abstract description 19
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 18
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 18
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 16
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 42
- 239000011505 plaster Substances 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 238000003756 stirring Methods 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 27
- 239000000758 substrate Substances 0.000 claims description 25
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 23
- 239000000017 hydrogel Substances 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000000853 adhesive Substances 0.000 claims description 18
- 230000001070 adhesive effect Effects 0.000 claims description 18
- 239000004744 fabric Substances 0.000 claims description 15
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 15
- 241000218176 Corydalis Species 0.000 claims description 14
- 239000013521 mastic Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 230000008961 swelling Effects 0.000 claims description 13
- 239000012467 final product Substances 0.000 claims description 12
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 10
- 241000195474 Sargassum Species 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 7
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 5
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical group CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 4
- 238000009941 weaving Methods 0.000 claims description 4
- 239000012876 carrier material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 35
- 208000002193 Pain Diseases 0.000 abstract description 31
- 230000036407 pain Effects 0.000 abstract description 31
- 210000004369 blood Anatomy 0.000 abstract description 26
- 239000008280 blood Substances 0.000 abstract description 26
- 230000017531 blood circulation Effects 0.000 abstract description 16
- 230000001105 regulatory effect Effects 0.000 abstract description 11
- 230000005906 menstruation Effects 0.000 abstract description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 6
- 210000003205 muscle Anatomy 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 210000001835 viscera Anatomy 0.000 abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 239000004310 lactic acid Substances 0.000 abstract description 4
- 235000014655 lactic acid Nutrition 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 238000007599 discharging Methods 0.000 abstract 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 43
- 238000009472 formulation Methods 0.000 description 22
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 20
- 229960001367 tartaric acid Drugs 0.000 description 20
- 210000000481 breast Anatomy 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 230000001737 promoting effect Effects 0.000 description 17
- 206010020880 Hypertrophy Diseases 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 10
- 229960001603 tamoxifen Drugs 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000003163 gonadal steroid hormone Substances 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 208000019255 Menstrual disease Diseases 0.000 description 5
- 235000011203 Origanum Nutrition 0.000 description 5
- 240000000783 Origanum majorana Species 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000004396 mastitis Diseases 0.000 description 5
- 210000002445 nipple Anatomy 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000002390 adhesive tape Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010006272 Breast mass Diseases 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010049077 Hernia pain Diseases 0.000 description 3
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
- 241000717739 Boswellia sacra Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- 240000009138 Curcuma zedoaria Species 0.000 description 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000004863 Frankincense Substances 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 241001057584 Myrrha Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 229950002007 estradiol benzoate Drugs 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 208000024756 faint Diseases 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000003502 gasoline Substances 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- -1 wherein Chemical compound 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical class CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241001290610 Abildgaardia Species 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 206010006312 Breast swelling Diseases 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241001550206 Colla Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 240000003271 Leonurus japonicus Species 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241000158728 Meliaceae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241000124463 Paeonia sterniana Species 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 229920002978 Vinylon Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 108010037528 lactotropin Proteins 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0625—Warming the body, e.g. hyperthermia treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
- A61N2005/066—Radiation therapy using light characterised by the wavelength of light used infrared far infrared
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a matrix for an external patch and the external patch as well as a mammary gland hyperplasia treating patch prepared from the matrix. The matrix is prepared from all or part of glycerol, ethylenediaminetetraacetic acid, ethylparaben, sodium polyacrylate, crospovidone, far-infrared powder, tartaric acid, sodium carboxymethylcellulose, gelatin, polyvinyl alcohol, a penetrating agent, triethanolamine and purified water. The mammary gland hyperplasia treating patch is prepared from the matrix and a medicinal extract or the matrix. The matrix for the external patch has the functions of relaxing a muscle, driving oxygen and a nutrient in a capillary network to exchange, discharging aged wastes of a fatigue substance, lactic acid and the like, which are accumulated in a body, and removing internal turgescence. The external patch has a certain function of relieving pain. The mammary gland hyperplasia treating patch has the functions of clearing away heat and toxic material, removing turgescence, eliminating stagnation, activating blood circulation to dissipate blood stasis, regulating menstruation, relieving pain, unblocking viscera and inducing the menstruation to relieve menalgia, further, is quick in effect taking, good in curative effect, less in the dosage of the penetrating agent and few in side effects, and can be used for treating various kinds of mammary gland hyperplasia.
Description
Technical field
The present invention relates to a kind of external use plaster substrate and external use plaster that this substrate is made and cyclomastopathy patch, belong to the technical field of medicine or medical apparatus and instruments。
Technical background
Cyclomastopathy is the disease that a kind of gynecological is common。It is apt to occur in the middle-aged women about 25-39 year, because being women's sexual function the most vigorous period during this period of time。Showing as the different parts single-shot of breast or multiple grow some lumps, quality is soft, and obscure boundary is movable, is often accompanied by pain in various degree。Especially, after the moon is premenstrual, tired or during the anxious state of mind such as angry (traditional Chinese medical science claims the stagnation of QI), lump increases, and pain increases the weight of, and after menstruation, lump is obviously reduced, pain relief。Pain is usually distending pain, little tingle。Should reminding, cyclomastopathy changes the possibility into mazalgia, if so suffering from mammary gland have hypertrophy time relatively elder, should remove examination in hospital, in order to diagnose and treat in time。In general, women's sentimentality, one is unsatisfactory, and the fire of conscience is sprung into life, and Liver Channel lactogenesis follows row two side of body, causes that stagnation of QI expectorant coagulates in breast。So, the traditional Chinese medical science is generally adopted the method treatment of soothing liver-QI for relieving depression, promoting the circulation of QI and reducing phlegm。Furthermore it is also possible to " Qi-tonifying drug " of some Colla cornus cervis of fit applications etc, can gas in promoting the circulation of blood, thus it is best to control breast disease effect。
At present, the method treating cyclomastopathy mainly has operative therapy and pharmacotherapy。Expenses of surgical treatment is high, and brings misery to patient, postoperative can produce stasis of blood trace over the course for the treatment of, directly influences the profile of breast and attractive in appearance, and the medicines of great majority treatment cyclomastopathy, unsatisfactory curative effect, side effect is big, is unfavorable for healthy。
Summary of the invention:
The technical problem to be solved is in that, it is provided that external use plaster and cyclomastopathy that a kind of external use plaster substrate and this substrate are made are pasted。Described external use plaster substrate can make Marjoram Extract, accelerates blood circulation, reduces penetrating agent consumption;Make body interior warm simultaneously, relax one's muscles, drive oxygen and the nutrient exchange of capillary network, and get rid of the accumulation aging refuse such as internal fatigue substances and lactic acid to swollen in eliminating。Described external use plaster has certain lenitive effect。Described cyclomastopathy patch has a heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, blood circulation promoting and blood stasis dispelling, blood circulation promoting and blood stasis dispelling, menstruction regulating and pain relieving, effect of the logical internal organs of a surname and inducing menstruation to relieve menalgia, and onset rapidly, good effect, penetrating agent make that consumption is less, side effect is less。Can be used for the cyclomastopathy treated caused by a variety of causes。
For solving above-mentioned technical problem, the present invention realizes by the following technical solutions: a kind of external use plaster substrate, calculate according to composition by weight, by being partly or entirely prepared from glycerol 10-60 part, ethylenediaminetetraacetic acid 0.01-10 part, ethyl hydroxybenzoate 0.01-0.4 part, sodium polyacrylate 1-20 part, polyvinylpolypyrrolidone 1-20 part, far-infrared powder 1-20 part, tartaric acid 0.1-10 part, sodium carboxymethyl cellulose 1-20 part, gelatin 0.1-15 part, polyvinyl alcohol 0.5-15 part, penetrating agent 0.1-10 part, triethanolamine 0.1-5 part and purified water 100-200 part。
In aforesaid external use plaster substrate, calculate according to composition by weight, by being partly or entirely prepared from glycerol 30-40 part, ethylenediaminetetraacetic acid 0.1-1 part, ethyl hydroxybenzoate 0.1-0.4 part, sodium polyacrylate 5-15 part, polyvinylpolypyrrolidone 5-15 part, far-infrared powder 5-15 part, tartaric acid 1-4 part, sodium carboxymethyl cellulose 6-12 part, gelatin 1-6 part, polyvinyl alcohol 3-9 part, penetrating agent 1-6 part, triethanolamine 1-1.6 part and purified water 140-160 part。
In aforesaid external use plaster substrate, calculate according to composition by weight, by being partly or entirely prepared from glycerol 35 parts, ethylenediaminetetraacetic acid 0.5 part, ethyl hydroxybenzoate 0.2 part, sodium polyacrylate 10 parts, polyvinylpolypyrrolidone 5 parts, far-infrared powder 5 parts, 2 parts of tartaric acid, sodium carboxymethyl cellulose 9 parts, 3 parts of gelatin, polyvinyl alcohol 6 parts, penetrating agent 3 parts, triethanolamine 1.3 parts and purified water 150 parts。
In aforesaid external use plaster substrate, described penetrating agent is azone;Or be prepared from after being mixed by the Borneolum Syntheticum 10-30 part calculated by weight, Mentholum 50-65 part, Oleum Cinnamomi 10-20 part and natural camphor 5-15 part;
Specifically, described penetrating agent calculates by weight, Borneolum Syntheticum 10-30 part, Mentholum 50-65 part, Oleum Cinnamomi 10-20 part and natural camphor 5-15 part are prepared from after mixing。
A kind of external use plaster, counts by weight percentage, aforesaid external use plaster substrate 80%-100%, drug extract or medicated powder surplus is prepared from。
In aforesaid external use plaster, described external use plaster is hydrogel adhesive, and the carrier material used by described hydrogel adhesive is non-weaving cloth, and described non-weaving cloth is for refusing water cloth。
In aforesaid external use plaster, the preparation method of described external use plaster is:
1. take polyvinyl alcohol, gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A;
2. take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone, ethyl hydroxybenzoate and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 0.5-1.5 hour, obtain solution B;
3. take drug extract or medicated powder, tartaric acid, triethanolamine are sequentially added in solution A, stir 5-15 minute, after mix homogeneously, obtain solution C;Or take tartaric acid, triethanolamine is sequentially added in solution A, stir 5-15 minute, after mix homogeneously, obtain solution C;
4. take penetrating agent and solution B adds in solution C, stir and make mastic in 2-7 minute;
5. the mastic made is spread evenly across and refuses, on water cloth, to dry, cut into slices, to obtain final product;
Specifically, the preparation method of described external use plaster is:
1. take polyvinyl alcohol, gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A;
2. take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone, ethyl hydroxybenzoate and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 2 hours, obtain solution B;
3. take drug extract, tartaric acid, triethanolamine are sequentially added in solution A, stir 10 minutes, after mix homogeneously, obtain solution C;Or take tartaric acid, triethanolamine is sequentially added in solution A, stir 10 minutes, after mix homogeneously, obtain solution C;
4. take penetrating agent and solution B adds in solution C, stir and make mastic in 5 minutes;
5. the mastic made is spread evenly across and refuses, on water cloth, to dry, cut into slices, to obtain final product。
A kind of cyclomastopathy patch, for aforesaid external use plaster, wherein, described drug extract calculates according to composition by weight, Herba Taraxaci 10-20 part, Radix Bupleuri 5-14 part, Pericarpium Citri Reticulatae 5-14 part, Rhizoma Cyperi 5-14 part, Pericarpium Citri Reticulatae Viride 5-15 part, Rhizoma Corydalis 6-18 part, Fructus Toosendan 6-18 part, Poria 6-18 part, Radix Paeoniae Alba 6-18 part, Radix Curcumae 6-18 part, Sargassum 6-18 part, Rhizoma Curcumae 6-18 part, Herba Leonuri 10-20 part, Retinervus Luffae Fructus 1-8 part and Spica Prunellae 7-15 part are prepared from。
In aforesaid cyclomastopathy patch, described drug extract is prepared from by Herba Taraxaci 15 parts, Radix Bupleuri 9 parts, Pericarpium Citri Reticulatae 9 parts, Rhizoma Cyperi 9 parts, 10 parts of Pericarpium Citri Reticulatae Viride, Rhizoma Corydalis 12 parts, Fructus Toosendan 12 parts, 12 parts of Poria, the Radix Paeoniae Alba 12 parts, Radix Curcumae 12 parts, Sargassum 12 parts, Rhizoma Curcumae 12 parts, Herba Leonuri 15 parts, Retinervus Luffae Fructus 4 parts and Spica Prunellae 11 parts。
In aforesaid cyclomastopathy patch, the preparation method of described drug extract is: take recipe quantity medical material, adds 6-8 times amount soak by water secondary, each 1-3h, filters, merging filtrate, it is the water extracted immersing paste of 1.10-1.20 that filtrate is concentrated into relative density when 60 DEG C, adds ethanol in the water extracted immersing paste, stirring while adding, its alcohol content is made to reach 70%, mixing, stand 24-48 hour, take supernatant, reclaiming ethanol, when supernatant concentration is to 60 DEG C, relative density is the extractum of 1.2-1.30, to obtain final product;
Specifically, the preparation method of described drug extract is: take recipe quantity medical material, boiling secondary, first time adds 8 times amount soak by water 2h, and second time adds the soak by water 1.5h of 6 times amount, filters, merging filtrate, it is the water extracted immersing paste of 1.10-1.20 that filtrate is concentrated into relative density when 60 DEG C, adds ethanol in the water extracted immersing paste, stirring while adding so that it is alcohol content reaches 70%, mixing, stand 36 hours, take supernatant, reclaim ethanol, when supernatant concentration is to 60 DEG C, relative density is the extractum of 1.2-1.30, to obtain final product。
External use plaster substrate of the present invention is by being partly or entirely prepared from glycerol, ethylenediaminetetraacetic acid, ethyl hydroxybenzoate, sodium polyacrylate, polyvinylpolypyrrolidone, far-infrared powder, tartaric acid, sodium carboxymethyl cellulose, gelatin, polyvinyl alcohol, penetrating agent, triethanolamine and purified water, wherein, glycerol and glycerol, be without the sweet clear and bright thick liquid of color and taste。Odorless。There is warm sweet taste。It is commonly called as glycerol, moisture can be absorbed from air, also can absorb hydrogen sulfide, Blausure (German) and sulfur dioxide。It is insoluble in benzene, chloroform, carbon tetrachloride, Carbon bisulfide, petroleum ether and oils。Glycerol is the framework ingredient of triglyceride molecule。When human body takes in edible fat, triglyceride therein decomposes through internal metabolism, forms glycerol and is stored in adipose cell。Therefore, the end product of Triglyceride Metabolism in Patients is glycerol and fatty acid。Can be used as solvent, lubricant, medicament and sweeting agent。Ethylenediaminetetraacetic acid energy and Mg2+、Ca2+、Mn2+、Fe2+Deng a kind of chelating agen that bivalent metal ion combines。Owing to the effect of most nucleic acid enzymes and some protease needs Mg2+, therefore the conventional inhibitor doing nuclease, protease;Can also be used for the heavy-metal ion removal inhibitory action to enzyme。Ethyl hydroxybenzoate is white crystals thing, mildly bitter flavor, fiber crops of burning。It is mainly used as the sterilization antiseptic of food, cosmetics, medicine, is also used for feed anticorrosion agent。Sodium polyacrylate is a kind of new functional macromolecule material and important chemical products, and solid product is white (or light yellow) bulk or powder, and liquid form product is colourless (or faint yellow) thick liquid。It is dissolved in the media such as cold water, warm water, glycerol, propylene glycol, variations in temperature is stable, there is the effect of fixing metal ions, the metal ion negative influence to product can be stoped, be a kind of surfactant with multiple property。Polyvinylpolypyrrolidone is water-insoluble tablet disintegrant, direct compression and in dry or wet pelletizing press sheet technique working concentration be 2-5%;Polyvinylpolypyrrolidone can show rapidly high capillary activity and excellent hydration capability, almost without the tendency of gel;Research shows: the size of polyvinylpolypyrrolidone granule affects the disintegrate of antipyretic-antalgic sheet strongly, and what polyvinylpolypyrrolidone that granule is big was smaller can play disintegration faster。Polyvinylpolypyrrolidone is very excellent disintegrating agent, uses 1-2% in tablets, just can obtain the disintegration of other conventional common disintegrants, and there is good re-workability, namely reclaim and add man-hour, it is not necessary to add the disintegrating agent of volume, be referred to as super-disintegrant。Tartaric acid (tartaricacid), i.e. 2,3 dihydroxybutanedioic acid, is that a kind of carboxylic acid is present in various plants if Fructus Vitis viniferae and tamarind are also one of organic acid main in wine。Food can be made to have tart flavour as the antioxidant added in food。The maximum purposes of tartaric acid is beverage additive。Also it is pharmaceutical industries raw material。In mirror industry processed, tartaric acid is an important auxiliary agent and reducing agent, it is possible to control the formation speed of silver mirror, it is thus achieved that very homogeneous coating。Sodium carboxymethyl cellulose, (also known as: sanlose, carboxymethyl cellulose, CMC, Carboxymethyl, CelluloseSodium, SodiumsaltofCaboxyMethylCellulose) it is that the world today uses cellulose kind widest in area, that consumption is maximum。Food industry is used as thickening agent, medical industry is used as pharmaceutical carrier, daily chemical industry is used as adhesive, resists dignified dose again。Printing and dyeing industry is used as the protecting colloid etc. of sizing agent and printing gum。Can as oil recovery fracturing fluid composition in petrochemical industry。Gelatin (Gelatin), it does not have fixing structure and relative molecular weight, is degraded by the collagenous portion in the connective tissues such as animal skin, bone, sarolemma, flesh evil spirit and becomes thin slice or the powder of white or faint yellow, translucent, micro-strip gloss;It is a kind of colorless and odorless, non-volatility, transparent hard amorphous material, dissolve in hot water, insoluble in cold water, but can slowly imbibition soften, gelatin can absorb the water being equivalent to weight 5-10 times。Gelatin is one of very important native biopolymer material, has been widely used in food, medicine and chemical industry。Polyvinyl alcohol, organic compound, white plates, cotton-shaped or pulverulent solids, tasteless。It is dissolved in water (more than 95 DEG C), insoluble in gasoline, kerosene, vegetable oil, benzene, toluene, dichloroethanes, carbon tetrachloride, acetone, ethyl acetate, methanol, ethylene glycol etc.。It is slightly soluble in dimethyl sulfoxide。Polyvinyl alcohol is important industrial chemicals, is used for manufacturing Pioloform, polyvinyl acetal, resistance to gasoline pipeline and vinylon synthetic fibers, fabric-treating agent, emulsifying agent, paper coating, binding agent, glue etc.。The full name of penetrating agent (JFC) is fatty alcohol-polyoxyethylene ether, belongs to nonionic surfactant。Penetrating agent as the term suggests be osmosis, be also have fixing hydrophilic and oleophilic group, can align on the surface of solution, and can make the material that surface tension is remarkably decreased。Triethanolamine, i.e. three (2-ethoxy) amine, it is possible to regard the trihydroxy substituent of triethylamine as。Similar to other aminated compoundss, owing to nitrogen-atoms existing lone pair electrons, triethanolamine tool alkalescence, it is possible to generate salt with mineral acid or organic acid reaction。
The external use plaster that above-mentioned substrate combination is made has certain lenitive effect。Owing to external use plaster is percutaneous drug administration preparation, medicine need to penetrate into body, generation effect by keratodermatitis etc., and therefore general onset time is longer, generally adopts addition penetrating agent to promote drug osmotic。But general chemical enhancers has certain side effect, life-time service may cause skin uncomfortable, external use plaster of the present invention adds far-infrared powder in substrate, the far infrared that far-infrared powder produces is also known as " life light wave ", close with the frequency of vibration of human inner cell's molecule, after its infiltration is internal, the atom of human body cell and the resonance of molecule will be caused, through resonant absorption, between molecule, frictional heat forms thermal response, promotes subcutaneous deep temperature to rise, and makes Marjoram Extract, accelerate blood circulation, reduce penetrating agent consumption。In addition, after substrate of the present invention adds far-infrared powder, the deep and thorough power of far infrared is up to muscle arthrosis depths, make body interior warm, relax one's muscles, drive oxygen and the nutrient exchange of capillary network, and get rid of the accumulation aging refuse such as internal fatigue substances and lactic acid to swollen in eliminating, relax the effect ached remarkable。
Cyclomastopathy of the present invention patch is prepared from by Herba Taraxaci, Radix Bupleuri, Pericarpium Citri Reticulatae, Rhizoma Cyperi, Pericarpium Citri Reticulatae Viride, Rhizoma Corydalis, Fructus Toosendan, Poria, the Radix Paeoniae Alba, Radix Curcumae, Sargassum, Rhizoma Curcumae, Herba Leonuri, Retinervus Luffae Fructus, Spica Prunellae and adjuvant。Wherein, Herba Taraxaci (Classification system: TaraxacummongolicumHand.-Mazz.) Compositae, Dandelion herbaceos perennial。Nature and flavor: bitter sweet, cold。Gui Jing: entering liver, stomach warp, function cures mainly: heat-clearing and toxic substances removing, diuresis eliminating stagnation。Control acute mastitis, lymphadenitis, scrofula, furuncle carbuncle toxin, acute conjunctivitis, cold, fever, acute tonsillitis, acute bronchitis, gastritis, hepatitis, cholecystitis, urinary tract infection。Radix Bupleuri, Chinese medicine name。For the medical herbs that " Chinese Pharmacopoeia " includes, medicinal part is the dry root of umbelliferae bupleurum or Radix Bupeuri Scorzonerfolii.。Nature and flavor are bitter, be slightly cold, and return liver, gallbladder meridian。There are reconciling superficies and interior, effect of soothing the liver yang invigorating。For cold, fever, alternate attack of chill and fever, malaria, stagnation of QI due to depression of the liver, sternal rib pain, proctoptosis, uterine prolapse, menoxenia。Pericarpium Citri Reticulatae, Chinese medicine name。Dry mature skin for rutaceae orange CitrusreticulataBlanco and variety thereof。Bitter in the mouth, pungent, warm in nature, there is regulating qi-flowing for strengthening spleen, effect of drying dampness to eliminate phlegm。For distension and fullness in the abdomen, lack of appetite and vomiting, cough with copious phlegm。Rhizoma Cyperi, CyperusrotundusL., Chinese medicine name。Dry rhizome for sedge dried tuber。Nature and flavor: hardship pungent, micro-, micro-sweet are flat。Return liver, spleen, tri-jiao channel。There is dispersing the stagnated live-QI to relieve the stagnation of QI, regulating the flow of QI to ease the stomach, effect of menstruction regulating and pain relieving。Can be used for for stagnation of QI due to depression of the liver, distending pain in the chest and hypochondrium, hernia pain, distending pain of the breast, stagnation of QI in spleen and stomach, gastral cavity abdomen painful abdominal mass is vexed, distension pain, menoxenia, amenorrhea dysmenorrhea。Pericarpium Citri Reticulatae Viride, Chinese medicine name。Peel for the dry young fruit of rutaceae orange CitrusreticulataBlanco and variety thereof or immature fruit。Bitter in the mouth, pungent, warm in nature。Return liver, gallbladder, stomach warp。There is soothing the liver dispelling the stagnated QI, effect that removing food stagnancyization is stagnant。For distending pain in the chest and hypochondrium, hernia pain, nodules of the breast, acute mastitis, stagnation of QI due to dyspepsia, abdominal distention。Rhizoma Corydalis (CorydalisyanhusuoW.T.WangexZ.Y.SuetC.Y.Wu), has another name called: Rhizoma Corydalis, corydalis tuber, rhizoma corydalis, Rhizoma Corydalis etc.。It is Papaveraceae, Corydalis herbaceos perennial, nature and flavor: pungent;Bitter;Temperature;Nontoxic。Gui Jing: liver;Stomach;The heart;Lung;Spleen channel。Cure mainly: invigorate blood circulation;Dissipating blood stasis;Regulate the flow of vital energy;Pain relieving。Main trusted subordinate's all pains of waist knee joint;Menoxenia;Lump in the abdomen;Metrorrhagia;Puerperal blood faints;Lochiorrhea;Traumatic injury。Fructus Toosendan, Chinese medicine name。Dry mature fruit for Meliaceae plant Fructus Toosendan MeLiatoosendanSieb.etZucc.。Nature and flavor: bitter, cold。Return liver, small intestinal, bladder warp。There is soothing the liver expelling the heat-evil, promoting the circulation of QI to relieve pain, effect of parasite killing。For pathogenic fire derived from stagnation of liver-QI, the breast side of body, abdominal distention, hernia pain, abdominal pain due to worm stagnation。Poria, Chinese medicine name。Dry sclerotia for On Polyporaceae Poria Poriacocos (Schw.) Wolf。Sweet in the mouth, light, property is put down。GUIXIN, lung, spleen, kidney channel。Promoting diuresis to eliminate damp pathogen, spleen invigorating, mind calming。For edema oliguria, phlegm retention vertigo and palpitation, insufficiency of the spleen lack of appetite, have loose bowels in loose stool, irritability, palpitation with fear insomnia。The Radix Paeoniae Alba (formal name used at school: PaeonialactifloraPall.), also referred to as Paeonia sterniana Fletcher in Journ., is Ranunculaceae Paeonia plant。Suppressing the hyperactive liver pain relieving, nourishing blood for regulating menstruation, astringing YIN to stop sweating。For dizziness of having a headache, hypochondriac pain, stomachache, limb pain twin, blood deficiency and yellow complexion, menoxenia, spontaneous perspiration, night sweat。Radix Curcumae, Chinese medicine name。Dried root for zingiberaceous plant RADIX CURCUMAE CurcumarcenyujinY, H.ChenetC.Ling, Rhizoma Curcumae Longae CurcumalongaL., Guangxi zedoary CurcumakwangsiensisS.G.LeeetC.F.Liang or Rhizoma Curcumae CurcumaphaeocaulisVal.。Nature and flavor: pungent, bitter, cold。Return liver, the heart, lung meridian。Promoting blood circulation and stopping pain, promoting QI circulation for relieving depression, clear away heart-fire removing heat from blood, effect of promoting the function of the gallbladder to alleviate jaundice。Coercing twinge for breast, obstruction of qi in the chest and cardialgia, amenorrhea dysmenorrhea, distending pain of the breast, calentura coma, epilepsy is gone mad, and heat in blood tells nosebleed, jaundice dark coloured urine。Sargassum, Classification system: SARGASSUM, nature and flavor: bitter in the mouth, salty, cold in nature, nontoxic。Gui Jing: lung;Spleen;Kidney;Liver stomach warp。Effect: softening the hard mass;Expectorant;Diuretic;Detumescent。Thyromegaly, item submental lymph nodes tuberculosis。Eliminating stagnation gas carbuncle, abdomen inner product block, distending pain, abdomen hollow are rung。Also can descend 12 kinds of edema, treat and between skin, gather sudden and violent bursting, stay depressed heat, diuresis。Cure mainly: scrofula;Goiter;Gather;Edema;Beriberi;Painful and swollen testis;(Epileptic is ruined) hernia。Rhizoma Curcumae, Latin name: Curcumazedoaria (Christm.) Rosc., Rhizoma Curcumae is Zingiberaceae, Curcuma perennial root draft, meridian distribution of property and flavor: pungent, bitter, temperature。Return liver, spleen channel。There are removing blood stasis circulation of qi promoting, removing food stagnancy pain relieving。For abdominal pain due to blood stasis, hepatosplenomegaly, trusted subordinate's distending pain, gathering, women's blood stasis amenorrhea, traumatic injury is had a pain effect of eating accumulation。Herba Leonuri, Classification system: Leonurusartemisia (Laur.) S.Y.HuF, for Labiatae, mother wort plant, summer-flowering。Acrid in the mouth is bitter, cool, invigorates blood circulation, silt of dispelling, regulating menstruation, disappear water, treats menoxenia, and vaginal bleeding during pregnancy is had difficult labour, retention of placenta, puerperal blood faints, abdominal pain due to blood stasis, metrorrhagia and metrostaxis, hematuria, rushes down blood, carbuncle skin infection。Retinervus Luffae Fructus, VegetableSpongeofLuffa, for the vascular bundle of cucurbitaceous plant Fructus Luffae or the mature fruit of Guangdong Fructus Luffae。There is dredge the meridian passage, effect of removing toxic substances and promoting subsidence of swelling。Spica Prunellae (formal name used at school: PrunellavulgarisL), the property of medicine: pungent, bitter, cold。Return liver, gallbladder meridian。Effect: clearing away heat-fire, improving eyesight, mass dissipating and swelling eliminating。
Drug extract of the present invention with Herba Taraxaci, Radix Bupleuri for principal agent, wherein Herba Taraxaci heat-clearing and toxic substances removing, dispersing swelling and dissipating binds (especially kind disappear acute mastitis), Radix Bupleuri a surname thoroughly dredges and reaches, compatible with Pericarpium Citri Reticulatae Viride, Pericarpium Citri Reticulatae, Rhizoma Cyperi, Rhizoma Corydalis, Fructus Toosendan, there is depressed liver-energy dispersing and QI regulating pain relieving, adjust the merit of smooth QI and blood;Poria, Radix Paeoniae Alba spleen invigorating, easing the affected liver to relieve pain;Radix Curcumae depressed liver-energy dispersing and QI regulating, blood circulation promoting and blood stasis dispelling;Sargassum vanishing sputum and dispelling knot;Rhizoma Curcumae, Herba Leonuri blood circulation promoting and blood stasis dispelling, menstruction regulating and pain relieving, stagnant with mutually 5 promoting the circulation of blood of Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Spica Prunellae purging liver-heat, to change strongly fragrant solution and be tired of, Retinervus Luffae Fructus is apt to, into meridians, removing obstruction in the collateral to relieve pain and Herba Taraxaci compatibility, specially control carbuncle sore tumefacting virus, acute mastitis。If the additionally obvious patient of distending pain of the breast, it is also possible to increasing Olibanum (processed), Myrrha (processed) on the basis of this side, Olibanum (processed) is apt to key to regulate the flow of vital energy, the kind blood stasis dispelling of Myrrha (processed) is with treating blood disorders, and two medicines share to strengthen the effect of the logical internal organs of a surname, inducing menstruation to relieve menalgia。Said medicine prescription, each raw material has good synergism, plays heat-clearing and toxic substances removing altogether, dispersing swelling and dissipating binds (the especially kind acute mastitis that disappears), blood circulation promoting and blood stasis dispelling, effect of the logical internal organs of a surname and inducing menstruation to relieve menalgia, the cyclomastopathy caused by a variety of causes can be treated, evident in efficacy, have no side effect。
The extractum that said medicine is made and substrate combination of the present invention, in the cyclomastopathy made patch, far-infrared powder can make Marjoram Extract, accelerate blood circulation, the absorption of medicine can be promoted, improve the utilization rate of medicine, so that cyclomastopathy of the present invention patch onset is rapid, better efficacy。
In addition, cyclomastopathy of the present invention patch makes hydrogel adhesive, hydrogel adhesive is the high absorbency material of the macromolecular compound with three-dimensional net structure and water composition, it can swell in water significantly but be not dissolved in water, water is subject to the effects such as bonding, constraint and loses flowability, it is possible to keep certain shape。Hydrogel is widely present in nature, and is and human organ immediate synthetic material in structure and performance。Cyclomastopathy illing skin is more sensitive, patients is it is also possible that the ragazza of non-suckling, other patches such as cataplasma often need to by medical adhesive tape when using, after using medical adhesive tape to stick, not easily tear, and it is when tearing, skin irritation is very big, meanwhile, when other patches such as Babu cream make, usually adopting non-woven fabrics is carrier, and non-woven fabrics can ooze cloth, making use very inconvenient, the present invention adopts and refuses water cloth as carrier, uses also without medical adhesive tape, easy to use, when tearing, skin irritation is only small。
Applicant carried out following experiments, the provable present invention has effective effect;
Experimental example 1: pharmacodynamic study
One, analgesic experiment
1. external use plaster of the present invention, is prepared by embodiment 1;Dolantin。
2. animal
Kunming mouse, mice 30,18-22g, male and female half and half。
3. method and result
Mice 30,18-2g, male and female half and half, be randomly divided into 3 groups, often group 10: of the present invention group, dolantin group (25mg/kg), matched group (giving normal saline)。Except dolantin treated animal intraperitoneal injection, all the other treated animals smear medicine or opposite according to thing in left and right metapedes。After medicine 15 minutes, the right metapedes subcutaneous injection 2.5% formaldehyde 0.03ml of every Mus, and coating 1 time, in observing 15 minutes immediately, mice licks the number of times of right metapedes。Test data adopts t inspection to process, lower same。In Table 1。
Table 1 present invention inhibitory action (X ± SD) to licking foot reaction
Result: external use plaster formalin induced pain of the present invention has obvious analgesic activity, mice licks right metapedes number of times and significantly reduces, and compares with matched group, p < 0.05, it was shown that external preparation of the present invention has analgesic activity。
Two, treatment cyclomastopathy experiment
1, laboratory animal: select SPF level health unpregnancy Wistar rat 60,9 week old, body weight 200 ± 20) g, purchased from Chongqing City's Experimental Animal Center。
2, experimental technique
2.1 Experimental agents:
Invention formulation 1, is prepared according to embodiment 1。Invention formulation 2, is prepared by embodiment 2。Ointment for dispersing breast nodules, Qiqihar He Xiang Pharmaceutical Co produces, and 5g/ sheet makes ointment after grinding into powder, 4C Refrigerator store is standby;Tamoxifen, Shandong health pharmaceutcal corporation, Ltd produces, 10mg/ sheet;Estradiol benzoate, Shanghai General Pharmaceutical Co., ltd. produces, and concentration 2mg/ props up;Progesterone, Zhejiang Province XianJu Pharmacy stock Co., Ltd produces, and concentration 10mg/ props up。Serum Sex Hormones measures medicine box (Beijing North Institute of Biological Technology), 10% formaldehyde, 3% chloral hydrate。Prepared by tamoxifen ointment: tamoxifen 1g, Macrogol 4000 48.6g, Macrogol 4000 36.4g, propylene glycol 14mL。By tamoxifen ultrasonic dissolution in propylene glycol, Macrogol 4000 adds heat fusing and PEG400 mixing, and stirring adds in propylene glycol liquid, and stirring, to cold, to obtain final product。4C Refrigerator store is standby。
2.2 animal packet and administrations
Animal natural feeding starts experiment to adapt to environment in 5 days after the 2nd, 3 pairs of breast portion depilations。60 rats are divided into 6 groups by table of random number, often group 10, respectively blank group (A group), simple disease model group (B group), tamoxifen matched group (C group), ointment for dispersing breast nodules matched group (D group), of the present invention group 1 (E group) and of the present invention group 2 (F) group。
Modeling and administration: A group rat femoribus internus injecting normal saline 0.2mL/ pcs/day, continuous 30 days。All the other groups in femoribus internus intramuscular injection estradiol benzoate 0.5mg/kg/d, continuous 25 days, then intramuscular injection flavone 4mg/kg/d, continuous 5 days, manufacture Treatment of Hyperplasia of Mammary Glands in Animal Model。The 2nd, 3 pairs of breast place liniments of C, D group rat while modeling, wherein C group external application tamoxifen ointment 0.1g/ is only, and only, E group and F group external application invention formulation 1 respectively and invention formulation 2,0.1g/ are only for D group external application ointment for dispersing breast nodules 0.1g/。After the rat drug of topical application of each group, all soft massaging breasts 1min。
2.3 observation index and method
Observe the change of the mammary contour of rat every day。Animal, after 30 days, is pressed 300mg/kg through intraperitoneal injection of anesthesia with 3% chloral hydrate, respectively organizes diameter and the height of the 2nd nipple of rats with left with vernier caliper measurement by modeling and coating;Extract blood 3mL in ventral aorta, hand over Nuclear Medicine Department of Hospital Attached to Shandong Chinese Medical Univ., serum measured by radioimmunoassay sex hormone level;Taking the 2nd pair and the 3rd pair breast of rat, 10% formaldehyde is fixed, Pathology Deparment of Hospital Attached to Shandong Chinese Medical Univ., carries out specimens paraffin embedding slices, carries out histological observation after conventional H E dyeing under light microscopic。
2.4 rat breast tissue diagnostic criterias
According to or without cyclomastopathy disease and disease light and heavy degree, rat breast tissue being divided into 4 classes: without hypertrophy, slight hypertrophy, moderate hypertrophy, severe hypertrophy。Without hypertrophy: lobules of mammary gland is hypertrophy not, body of gland quantity is few, and acinus is not expanded, and is in state resting stage。Slight hypertrophy: indivedual acinuses have slight hypertrophy, without expansion, acinus and have secretions in conduit。Moderate hypertrophy: lobules of mammary gland major part hypertrophy, minority acinus has slight expansion, and adenomatosis level increases, acinus and have secretions in conduit。Severe hypertrophy: lobules of mammary gland major part hypertrophy, most acinuses have obvious expansion, and adenomatosis level increases。More secretions is had in acinus and conduit。Group cyclomastopathy degree each under light microscopic is classified by above-mentioned standard。
2.5 Processing for Data Analysis in Physics
SAS8.0 version statistical software is adopted to be analyzed。The comparison comparing employing variance analysis, each treatment group and matched group between measurement data group adopts t inspection。Ranked data CMH X 2 test。
3, experimental result
The measurement result of 3.1 rat height of nipples and diameter
Testing observation in the 30th day: blank group mammary contour is unchanged, other are respectively organized occurs breast swelling all to some extent, wherein notable with sick module change。The measurement result of each group rat height of nipples and diameter is in Table 2。
The measurement result (n=10, x ± s) of the 2nd height of nipples of rats with left and diameter respectively organized by table 2
Note: compare with simple disease model group,+P < 0.01;
Compare with tamoxifen matched group,#P < 0.01;
Compare with of the present invention group 1,&P<0.05。
As seen from table, invention formulation 1 and invention formulation 2 all can substantially suppress the change of the rat height of nipples caused by estrogen and progestogen modeling;Also can substantially suppress the change of rat papilla diameter caused by estrogen and progestogen modeling simultaneously, and invention formulation 2 is better than invention formulation 1。
3.2 respectively organize rat breast tissue morphological observation
Each group rat breast mammary gland tissue observed result is in Table 3。
Rat breast mammary gland tissue observation analysis respectively organized by table 3
Note: compare with simple disease model group,+P < 0.01;
Compare with tamoxifen matched group,#P < 0.01;
Compare with of the present invention group 1,&P<0.05。
As seen from table, subject hydrogel agent can significantly reduce the degree of cyclomastopathy。
3.3 respectively organize Serum Sex Hormones measurement result
Each group Serum Sex Hormones measurement result is in Table 4, table 5。
The measurement result (n=10, x ± s) of Serum Sex Hormones respectively organized by table 4
Note: compare with simple disease model group,+P < 0.01;
Compare with tamoxifen matched group,#P < 0.01;
Compare with of the present invention group 1,&P<0.05。
The measurement result (n=10, x ± s) of Serum Sex Hormones respectively organized by table 5
Note: compare with simple disease model group,+P < 0.01;
Compare with tamoxifen matched group,#P < 0.01;
Compare with of the present invention group 1,&P<0.05。
As seen from table: subject hydrogel agent can significantly reduce estrogen (E2) level of cyclomastopathy rat model, raise progestogen (P) level, substantially reduce cyclomastopathy rat model lactotropin level。Improve the level of serum testosterone (T) and lutropin (LH), and the level of Folliculogenesis element (FSH) can be reduced。
Experimental example 2: performance study
1 research project:
1.1 invention formulation 1, carry out system by embodiment 1 and make;
1.2 invention formulation 2, make by embodiment 2。
2, experimental technique:
2.1 tacks: test according to [7 method A inclined-plane rolling ball method] prescriptive procedure in GB/T4852-2002 tack test method (rolling ball method), the tack of cyclomastopathy patch should no less than 5 seconds。The concrete method of inspection is as follows:
Taking invention formulation 1 and each 3 of invention formulation 2 respectively, remove lid lining, being placed in inclination angle is 300 hang plate central authorities, and cream is towards upper, and top, inclined-plane 10cm and bottom 15cm covers with mylar thick for 0.025mm。Centre reserves 5cm cream face, is freely rolled down along beveled top end by No. 5 steel balls, clings the cream face time and cannot be less than 5 seconds。
2.2 moistures: cyclomastopathy patch is measured by oven drying method, the moisture in cyclomastopathy patch 100g should be not less than 30g。The concrete method of inspection is as follows:
Take invention formulation 1 and each 3 of invention formulation 2 respectively, be laid in evaporating dish, accurately weighed w1, dry 3 hours at 100-105 DEG C, take out, be placed in exsiccator and let cool 30 minutes, accurately weighed w2, the weight according to less loss, calculate water content (%) in test sample。Computational methods are as follows:
2.3 far infrared wavelength tests take invention formulation 1 and each 10 of invention formulation 2 respectively, remove lid lining, check with far infrared detector。
3, experimental result:
3.1 tacks: invention formulation 1 and invention formulation 2 paste tack and be no less than 5 seconds;
3.2 moistures: the moisture 48g in invention formulation 1100g;With the moisture 52g in invention formulation 2100g。
3.3 far infrared waves: invention formulation 1 and invention formulation 2 far infrared wavelength are 10 μm~14 μm, and emissivity is 82.6% and 83.5%。
Conclusion: the viscosity of cyclomastopathy of the present invention patch is good, it is not necessary to just can be affixed on affected part by medical adhesive tape, decreases sending out of patient skin allergic conditions, and water content is high, is conducive to the absorption of active ingredient, better efficacy。Therefore cyclomastopathy of the present invention patch is functional。
Compared with prior art, have the advantages that
1. external use plaster of the present invention has certain lenitive effect。External use plaster of the present invention adds far-infrared powder in substrate, the far infrared that far-infrared powder produces is also known as " life light wave ", close with the frequency of vibration of human inner cell's molecule, after its infiltration is internal, the atom of human body cell and the resonance of molecule will be caused, through resonant absorption, between molecule, frictional heat forms thermal response, promotes subcutaneous deep temperature to rise, and makes Marjoram Extract, accelerate blood circulation, reduce penetrating agent consumption。In addition, after substrate of the present invention adds far-infrared powder, the deep and thorough power of far infrared is up to muscle arthrosis depths, make body interior warm, relax one's muscles, drive oxygen and the nutrient exchange of capillary network, and get rid of the accumulation aging refuse such as internal fatigue substances and lactic acid to swollen in eliminating, relax the effect ached remarkable。
2. cyclomastopathy of the present invention patch has heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, blood circulation promoting and blood stasis dispelling, blood circulation promoting and blood stasis dispelling, menstruction regulating and pain relieving, effect of the logical internal organs of a surname and inducing menstruation to relieve menalgia, can treat the cyclomastopathy caused by a variety of causes。
3. additionally, by drug extract and substrate combination of the present invention, in the cyclomastopathy made patch, far-infrared powder can make Marjoram Extract, accelerates blood circulation, it is possible to promotes the absorption of medicine, improve the utilization rate of medicine, so that cyclomastopathy of the present invention patch onset is rapid, better efficacy。And the cyclomastopathy patch made has that tack is good, water content is high, osmotic effect is good, and side effect is less waits beneficial effect。
Detailed description of the invention:
Embodiment 1:
Formula: glycerol 35g, ethylenediaminetetraacetic acid 0.5g, ethyl hydroxybenzoate 0.2g, sodium polyacrylate 10g, polyvinylpolypyrrolidone 5g, far-infrared powder 5g, tartaric acid 2g, sodium carboxymethyl cellulose 9g, gelatin 3g, polyvinyl alcohol 6g, penetrating agent 3g, triethanolamine 1.3g and purified water 150g;
The preparation of penetrating agent: be prepared from after being mixed by Borneolum Syntheticum 120g, Mentholum 58g, Oleum Cinnamomi 15g and natural camphor 10g。
Hydrogel adhesive processing technology:
1. take polyvinyl alcohol, gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A;
2. take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone, ethyl hydroxybenzoate and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 0.5-1.5 hour, obtain solution B;
3. take tartaric acid, triethanolamine is sequentially added in solution A, stirs 5-15 minute, after mix homogeneously, obtains solution C;
4. take penetrating agent and solution B adds in solution C, stir and make mastic in 2-7 minute;
5. the mastic made is spread evenly across and refuses, on water cloth, to dry, cut into slices, obtain hydrogel adhesive。
Embodiment 2:
The preparation of drug extract:
Drug extract prescription: Herba Taraxaci 15g, Radix Bupleuri 9g, Pericarpium Citri Reticulatae 9g, Rhizoma Cyperi 9g, Pericarpium Citri Reticulatae Viride 10g, Rhizoma Corydalis 12g, Fructus Toosendan 12g, Poria 12g, Radix Paeoniae Alba 12g, Radix Curcumae 12g, Sargassum 12g, Rhizoma Curcumae 12g, Herba Leonuri 15g, Retinervus Luffae Fructus 4g and Spica Prunellae 11g;
Preparation technology: taking recipe quantity medical material, boiling secondary, first time adds 8 times amount soak by water 2h, second time adds the soak by water 1.5h of 6 times amount, filters, merging filtrate, filtrate is concentrated into the water extracted immersing paste of relative density 1.10-1.20, adds ethanol in the water extracted immersing paste, stirring while adding, its alcohol content is made to reach 70%, mixing, stand 36 hours, take supernatant, reclaiming ethanol, supernatant concentration, to the extractum of relative density 1.2-1.30, to obtain final product;
The preparation of hydrogel adhesive:
Hydrogel adhesive prescription: drug extract 10g, glycerol 35g, ethylenediaminetetraacetic acid 0.5g, ethyl hydroxybenzoate 0.2g, sodium polyacrylate 10g, polyvinylpolypyrrolidone 5g, far-infrared powder 5g, tartaric acid 2g, sodium carboxymethyl cellulose 9g, gelatin 3g, polyvinyl alcohol 6g, penetrating agent 3g, triethanolamine 1.3g and purified water 150g;
Penetrating agent prescription: the preparation of penetrating agent: be prepared from after being mixed by Borneolum Syntheticum 120g, Mentholum 58g, Oleum Cinnamomi 15g and natural camphor 10g。
Hydrogel adhesive preparation technology:
1, take polyvinyl alcohol, gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A;
2, take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone, ethyl hydroxybenzoate and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 2 hours, obtain solution B;
3, take drug extract, tartaric acid, triethanolamine are sequentially added in solution A, stir 10 minutes, after mix homogeneously, obtain solution C;
4, take penetrating agent and solution B adds in solution C, stir and make mastic in 5 minutes;
5, the mastic made is spread evenly across refuses, on water cloth, to dry, cut into slices, to obtain final product。
Embodiment 3:
The preparation of hydrogel adhesive:
Hydrogel adhesive prescription: glycerol 40g, ethylenediaminetetraacetic acid 1g, polyvinylpolypyrrolidone 15g, far-infrared powder 15g, tartaric acid 4g, sodium carboxymethyl cellulose 12g, gelatin 6g, polyvinyl alcohol 9g, penetrating agent 6g and purified water 160g, described penetrating agent is azone。
Hydrogel adhesive preparation technology:
1. take gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A;
2. take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 1.5 hours, obtain solution B;
3. take tartaric acid to add in solution A, stir 15 minutes, after mix homogeneously, obtain solution C;
4. take penetrating agent and solution B adds in solution C, stir and make mastic in 7 minutes;
5. the mastic made is spread evenly across and refuses, on water cloth, to dry, cut into slices, to obtain final product。
Embodiment 4:
The preparation of drug extract:
Drug extract prescription: Herba Taraxaci 10g, Radix Bupleuri 5g, Pericarpium Citri Reticulatae 5g, Rhizoma Cyperi 5g, Pericarpium Citri Reticulatae Viride 5g, Rhizoma Corydalis 6g, Fructus Toosendan 6g, Poria 6g, Radix Paeoniae Alba 6g, Radix Curcumae 6g, Sargassum 6g, Rhizoma Curcumae 6g, Herba Leonuri 10g, Retinervus Luffae Fructus 1g and Spica Prunellae 7g;
Preparation technology: take recipe quantity medical material, adds 6 times amount soak by water secondaries, each 1h, filtering, merging filtrate, it is the water extracted immersing paste of 1.10-1.20 that filtrate is concentrated into relative density when 60 DEG C, ethanol is added in the water extracted immersing paste, stirring while adding so that it is alcohol content reaches 70%, mixing, stand 24 hours, take supernatant, reclaim ethanol, when supernatant concentration is to 60 DEG C, relative density is the extractum of 1.2-1.30, to obtain final product。
The preparation of hydrogel adhesive:
Hydrogel adhesive prescription: drug extract 5g, ethylenediaminetetraacetic acid 1g, polyvinylpolypyrrolidone 15g, far-infrared powder 15g, tartaric acid 4g, sodium carboxymethyl cellulose 12g, gelatin 6g, polyvinyl alcohol 9g, penetrating agent 6g and purified water 160g, described penetrating agent is azone。
Hydrogel adhesive preparation technology:
1. take gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A;
2. take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 1.5 hours, obtain solution B;
3. take drug extract and tartaric acid adds in solution A, stir 15 minutes, after mix homogeneously, obtain solution C;
4. take penetrating agent and solution B adds in solution C, stir and make mastic in 7 minutes;
5. the mastic made is spread evenly across and refuses, on water cloth, to dry, cut into slices, to obtain final product。
Claims (10)
1. an external use plaster substrate, it is characterized in that: calculate according to composition by weight, by being partly or entirely prepared from glycerol 10-60 part, ethylenediaminetetraacetic acid 0.01-10 part, ethyl hydroxybenzoate 0.01-0.4 part, sodium polyacrylate 1-20 part, polyvinylpolypyrrolidone 1-20 part, far-infrared powder 1-20 part, tartaric acid 0.1-10 part, sodium carboxymethyl cellulose 1-20 part, gelatin 0.1-15 part, polyvinyl alcohol 0.5-15 part, penetrating agent 0.1-10 part, triethanolamine 0.1-5 part and purified water 100-200 part。
2. external use plaster substrate as claimed in claim 1, it is characterized in that: calculate according to composition by weight, by being partly or entirely prepared from glycerol 30-40 part, ethylenediaminetetraacetic acid 0.1-1 part, ethyl hydroxybenzoate 0.1-0.4 part, sodium polyacrylate 5-15 part, polyvinylpolypyrrolidone 5-15 part, far-infrared powder 5-15 part, tartaric acid 1-4 part, sodium carboxymethyl cellulose 6-12 part, gelatin 1-6 part, polyvinyl alcohol 3-9 part, penetrating agent 1-6 part, triethanolamine 1-1.6 part and purified water 140-160 part。
3. external use plaster substrate as claimed in claim 2, it is characterized in that: calculate according to composition by weight, by being partly or entirely prepared from glycerol 35 parts, ethylenediaminetetraacetic acid 0.5 part, ethyl hydroxybenzoate 0.2 part, sodium polyacrylate 10 parts, polyvinylpolypyrrolidone 5 parts, far-infrared powder 5 parts, 2 parts of tartaric acid, sodium carboxymethyl cellulose 9 parts, 3 parts of gelatin, polyvinyl alcohol 6 parts, penetrating agent 3 parts, triethanolamine 1.3 parts and purified water 150 parts。
4. the external use plaster substrate as according to any one of claim 1-3, it is characterised in that: described penetrating agent is azone;Or be prepared from after being mixed by the Borneolum Syntheticum 10-30 part calculated by weight, Mentholum 50-65 part, Oleum Cinnamomi 10-20 part and natural camphor 5-15 part。
5. an external use plaster, it is characterised in that: counting by weight percentage, external use plaster substrate 80%-100% according to any one of claim 1-4, drug extract or medicated powder surplus are prepared from。
6. external use plaster as claimed in claim 5, it is characterised in that: described external use plaster is hydrogel adhesive, and the carrier material used by described hydrogel adhesive is non-weaving cloth, and described non-weaving cloth is for refusing water cloth。
7. external use plaster as claimed in claim 6, it is characterised in that: the preparation method of described external use plaster is:
(1) take polyvinyl alcohol, gelatin, sodium carboxymethyl cellulose purified water heating swelling after, obtain solution A;
(2) take after far-infrared powder, sodium polyacrylate, polyvinylpolypyrrolidone, ethyl hydroxybenzoate and ethylenediaminetetraacetic acid be sequentially added into glycerol, mixing, stir 0.5-1.5 hour, obtain solution B;
(3) take drug extract or medicated powder, tartaric acid, triethanolamine are sequentially added in solution A, stir 5-15 minute, after mix homogeneously, obtain solution C;Or take tartaric acid, triethanolamine is sequentially added in solution A, stir 5-15 minute, after mix homogeneously, obtain solution C;
(4) take penetrating agent and solution B adds in solution C, stir and make mastic in 2-7 minute;
(5) mastic made is spread evenly across refuses, on water cloth, to dry, cut into slices, to obtain final product。
8. a cyclomastopathy patch, it is characterized in that: the external use plaster according to any one of claim 5-7, wherein, described drug extract calculates according to composition by weight, Herba Taraxaci 10-20 part, Radix Bupleuri 5-14 part, Pericarpium Citri Reticulatae 5-14 part, Rhizoma Cyperi 5-14 part, Pericarpium Citri Reticulatae Viride 5-15 part, Rhizoma Corydalis 6-18 part, Fructus Toosendan 6-18 part, Poria 6-18 part, Radix Paeoniae Alba 6-18 part, Radix Curcumae 6-18 part, Sargassum 6-18 part, Rhizoma Curcumae 6-18 part, Herba Leonuri 10-20 part, Retinervus Luffae Fructus 1-8 part and Spica Prunellae 7-15 part are prepared from。
9. cyclomastopathy patch as claimed in claim 8, it is characterised in that: described drug extract is prepared from by Herba Taraxaci 15 parts, Radix Bupleuri 9 parts, Pericarpium Citri Reticulatae 9 parts, Rhizoma Cyperi 9 parts, 10 parts of Pericarpium Citri Reticulatae Viride, Rhizoma Corydalis 12 parts, Fructus Toosendan 12 parts, 12 parts of Poria, the Radix Paeoniae Alba 12 parts, Radix Curcumae 12 parts, Sargassum 12 parts, Rhizoma Curcumae 12 parts, Herba Leonuri 15 parts, Retinervus Luffae Fructus 4 parts and Spica Prunellae 11 parts。
10. cyclomastopathy is pasted as claimed in claim 8 or 9, it is characterized in that: the preparation method of described drug extract is: take recipe quantity medical material, add 6-8 times amount soak by water secondary, each 1-3h, filter, merging filtrate, it is the water extracted immersing paste of 1.10-1.20 that filtrate is concentrated into relative density when 60 DEG C, adds ethanol in the water extracted immersing paste, stirring while adding, its alcohol content is made to reach 70%, mixing, stand 24-48 hour, take supernatant, reclaiming ethanol, when supernatant concentration is to 60 DEG C, relative density is the extractum of 1.2-1.30, to obtain final product。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610044368.7A CN105688217A (en) | 2016-01-22 | 2016-01-22 | Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610044368.7A CN105688217A (en) | 2016-01-22 | 2016-01-22 | Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105688217A true CN105688217A (en) | 2016-06-22 |
Family
ID=56228515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610044368.7A Pending CN105688217A (en) | 2016-01-22 | 2016-01-22 | Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105688217A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108310155A (en) * | 2018-02-23 | 2018-07-24 | 广西中医药大学 | A kind of graphene curing mammary gland hyperplasia patch and preparation method thereof |
CN109224004A (en) * | 2018-12-10 | 2019-01-18 | 陕西太白山天然植物开发有限公司 | A kind of external use plaster and preparation method thereof for treating the proliferation of mammary gland |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102188580A (en) * | 2011-05-10 | 2011-09-21 | 浙江省中医药研究院 | Externally used traditional Chinese medicine composition and cataplasm for treating lobular hyperplasia of mammary gland, and preparation methods thereof |
CN102397443A (en) * | 2010-09-17 | 2012-04-04 | 复旦大学 | Stasis-dissipating pain-relieving cataplasm for treating hyperplasia of mammary glands and preparation method thereof |
CN103705937A (en) * | 2014-01-09 | 2014-04-09 | 贵州康琦药械有限公司 | Medicinal plaster substrate, medicinal plaster using the substrate and preparation method thereof |
CN105497261A (en) * | 2016-01-22 | 2016-04-20 | 贵州康琦药械有限公司 | Matrix of patch for external use and patch and sleeping-aid patch made from matrix |
-
2016
- 2016-01-22 CN CN201610044368.7A patent/CN105688217A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102397443A (en) * | 2010-09-17 | 2012-04-04 | 复旦大学 | Stasis-dissipating pain-relieving cataplasm for treating hyperplasia of mammary glands and preparation method thereof |
CN102188580A (en) * | 2011-05-10 | 2011-09-21 | 浙江省中医药研究院 | Externally used traditional Chinese medicine composition and cataplasm for treating lobular hyperplasia of mammary gland, and preparation methods thereof |
CN103705937A (en) * | 2014-01-09 | 2014-04-09 | 贵州康琦药械有限公司 | Medicinal plaster substrate, medicinal plaster using the substrate and preparation method thereof |
CN105497261A (en) * | 2016-01-22 | 2016-04-20 | 贵州康琦药械有限公司 | Matrix of patch for external use and patch and sleeping-aid patch made from matrix |
Non-Patent Citations (6)
Title |
---|
侯雪梅等: "水凝胶贴剂的研究进展及目前存在的问题", 《药学服务与研究》 * |
元英进: "《现代制药工艺学 下》", 31 January 2006 * |
吴文芝: "乳癖汤治疗乳腺增生病40例", 《实用中医药杂志》 * |
孟胜男: "《药剂学》", 30 September 2011 * |
屠佑堂: "《中医实用诊疗大全 下册》", 30 March 2013 * |
王广生: "《石油化工原料与产品安全手册》", 31 August 2010 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108310155A (en) * | 2018-02-23 | 2018-07-24 | 广西中医药大学 | A kind of graphene curing mammary gland hyperplasia patch and preparation method thereof |
CN109224004A (en) * | 2018-12-10 | 2019-01-18 | 陕西太白山天然植物开发有限公司 | A kind of external use plaster and preparation method thereof for treating the proliferation of mammary gland |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103041173B (en) | Traditional Chinese medicine external preparation for curing dermatitis and eczema and preparing method thereof | |
CN103751633A (en) | Traditional Chinese medicinal composition for treating varicose vein of lower limb and preparation method thereof | |
CN105688217A (en) | Matrix for external patch and external patch as well as mammary gland hyperplasia treating patch prepared from matrix | |
CN105662996A (en) | Traditional Chinese medicine mask for treating menstruation-associated acne | |
CN104547797A (en) | Dampness-affected analgesic cataplasm and preparation method thereof | |
CN103656572A (en) | Traditional Chinese medicine composition, traditional Chinese medicinal compound, plaster and preparation method thereof | |
CN103690849B (en) | Be used for the treatment of the Chinese medicine preparation of Superficial Thrombotic Phlebitis | |
CN104127831A (en) | Traditional Chinese medicine for treating pantalgia after childbirth caused by exogenous pathogen and preparation method thereof | |
CN103735792B (en) | A kind of medicine for the treatment of menoxenia and preparation method thereof | |
CN101390964A (en) | Cataplasm of traditional Chinese medicine for treating hyperosteogeny | |
CN104367946A (en) | Traditional Chinese medicine suppository for treating chronic endometritis and preparation method thereof | |
CN104208589A (en) | Medicine for treating hyperplasia of mammary glands | |
CN102614341B (en) | Chinese medicinal composition for promoting fracture healing | |
CN104352995A (en) | Medicine for treating gall-stone and preparation method thereof | |
CN115569167B (en) | Traditional Chinese medicine composition for treating burns and scalds as well as preparation method and application thereof | |
CN102091254A (en) | Traditional Chinese medicine composition for relieving swelling after cosmetic surgery and preparation method thereof | |
CN101822685A (en) | Application of asiaticoside | |
CN103933359A (en) | Pharmaceutical composition for dispelling keloid and preparation method of pharmaceutical composition | |
CN106138628A (en) | A kind of strong medicine ZHICHUANG GAO and preparation method thereof | |
CN105998290A (en) | Traditional Chinese medicine composition for treating early woman amenorrhea and preparing method thereof | |
CN114748557A (en) | Hot compress physiotherapy uterus warming patch for gynecology | |
CN105596687A (en) | Traditional Chinese medicine for treating perimenopausal syndrome | |
CN105535674A (en) | A medicine for treating chronic cervicitis | |
CN105288486A (en) | Uterine fibroid treating traditional Chinese medicine composition | |
CN103784722A (en) | Method for controlling estrus synchronization of maria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160622 |